Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to Do

Posted by Seth P. Lerner, MD, FACS | Apr 2023

Seth P. Lerner, MD, presented “Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to Do” at the 6th International Bladder Cancer Update on November 18, 2022, in Scottsdale, Arizona.

How to cite: Lerner, Seth P. “Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to Do” November 2022. Accessed Nov 2024. https://grandroundsinurology.com/prioritizing-the-optimal-therapy-for-t1-bladder-cancer-using-the-old-and-the-new-to-determine-what-to-do/

Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to Do – Summary

Seth P. Lerner, MD, Professor of Urology and Vice-chair for Faculty Affairs in the Scott Department of Urology, and Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program at Baylor University, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer and considers the future of treatment. Dr. Lerner details the importance of muscle in the specimen when staging the depth of invasion. He describes when a tumor should be classified as high-grade, and thus high-risk. T1 sub-staging reflects the depth of invasion, which has implications for risk, and therefore treatment. In almost all cases, re-resection is required. Enhanced cystoscopy, in combination with site-directed biopsies, helps detect carcinoma in situ (CIS). Dr. Lerner considers a case in which intravesical Bacillus Calmette-Guerin (BCG) weekly for 6 weeks is recommended. Dr. Lerner then reviews a second case in which a cystectomy is the best option for a large-volume multifocal T1HG plus unresectable TaHG tumor in the diverticulum. Dr. Lerner introduces a T1HG meta-analysis which associated factors such as lymphovascular invasion (LVI) and non-use of BCG with risk of recurrence. Dr. Lerner considers when initial radical cystectomy is appropriate. He discusses the applicability of up-front cystectomy in certain cases, such as patients with primary T1HG with large-volume or multifocal disease, or in cases of LVI. He continues by considering the variant histology that indicates cystectomy, such as micropapillary. He addresses a study that shows similar outcomes despite the immediacy of cystectomy in cases of HGT1 disease. Dr. Lerner describes the current review of BCG unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). He highlights the potential for combination therapy in high-risk patient populations. Dr. Lerner introduces T1HG subtypes, and how differing molecularly may have clinical implications.

About the 6th International Bladder Cancer Update:

The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.

For further educational activities from this conference, visit our collection page.

ABOUT THE AUTHOR

Seth P. Lerner, MD, FACS

Seth P. Lerner, MD, FACS, is Professor of Urology and Vice-Chair for Faculty Affairs in the Scott Department of Urology at the Baylor College of Medicine in Houston, Texas. He holds the Beth and Dave Swalm Chair in Urologic Oncology. Dr. Lerner is the Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program, also at Baylor.

Dr. Lerner earned his medical degree from the Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in Urologic Oncology and Reconstructive Surgery and joined the full-time Baylor faculty in 1992.

About The Author

Seth P. Lerner, MD, FACS

Seth P. Lerner, MD, FACS, is Professor of Urology and Vice-Chair for Faculty Affairs in the Scott Department of Urology at the Baylor College of Medicine in Houston, Texas. He holds the Beth and Dave Swalm Chair in Urologic Oncology. Dr. Lerner is the Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program, also at Baylor. Dr. Lerner earned his medical degree from the Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in Urologic Oncology and Reconstructive Surgery and joined the full-time Baylor faculty in 1992. Dr. Lerner’s clinical practice, education, and research activities are devoted to urologic oncology, particularly to lower and upper tract urothelial cancer. Dr. Lerner is the author of 228 peer-reviewed articles, co-editor of a comprehensive Textbook on Bladder Cancer, and founding co-editor-in-chief of the Bladder Cancer journal. His research interests include the use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, integrated proteogenomic analysis of bladder and upper urinary tract cancers, and outcomes of radical cystectomy and pelvic lymphadenectomy. Dr. Lerner has 30 years of experience as a clinical investigator for both National Cancer Institute (NCI) and industry-funded clinical trials. He is Principal Investigator of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy. He is active in the leadership of several national bladder cancer research enterprises, serving as chair of the Local Bladder Cancer committee of SWOG, founding and former co-chair of the NCI Bladder Cancer Task Force, and former co-chair of theNCI National Clinical Trials Network (NCTN) Genitourinary Steering Committee. He co-chaired the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer and was recently appointed to a 4-year term to the NCI Clinical Trials and Translational Research Advisory Committee. Dr. Lerner is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, is past chair of the Bladder Cancer Think Tank, and is co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is an active member of the prestigious American Association of Genitourinary Surgeons and is listed routinely among “America’s Top Doctors” and “Best Doctors in America.”

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat